<DOC>
	<DOCNO>NCT02021773</DOCNO>
	<brief_summary>The purpose study determine whether monthly subcutaneous administration LBR-101 safe provide migraine prevention patient chronic migraine .</brief_summary>
	<brief_title>Assessment LBR-101 In Chronic Migraine</brief_title>
	<detailed_description>Two distinct dos subcutaneous LBR-101 administer monthly compare placebo safety efficacy . The mean change baseline number cumulative headache hour measure 28-day period end week 12 .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Males female age 18 65 year age . A signed date informed consent document indicate subject inform pertinent aspect study include know potential risk available alternative treatment . Chronic migraine meeting diagnostic criterion list International Classification Headache Disorders ( ICHDIII beta version , 2013 ) Body Mass Index ( BMI ) 17.5 37.5 kg/m2 , total body weight 50 kg 120 kg inclusive . Demonstrated compliance electronic headache diary runin period headache data minimum 22/28 day ( 80 % diary compliance ) Onset chronic migraine age 50 year . Subject receive onabotulinum toxin A migraine medical cosmetic reason require injection head , face , neck 6 month prior study entry . Subject use medication contain opioids ( include codeine ) barbiturate ( include Fiorinal® , Fioricet® , combination contain butalbital ) 4 day per month treatment migraine reason . Failed &gt; 2 medication category &gt; 3 preventive medication ( within two medication category ) due lack efficacy prophylactic treatment episodic chronic migraine adequate therapeutic trial Treatment investigational drug device within 30 day study entry prior exposure monoclonal antibody target CGRP pathway .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Headache</keyword>
	<keyword>Migraine</keyword>
	<keyword>Chronic Migraine</keyword>
</DOC>